Evidence map›Paper›PMID 29205509›Full record

Observational studyMovement disorders : official journal of the Movement Disorder Society2018

Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.

Jennifer G Goldman, Howard Andrews, Amy Amara, Anna Naito, Roy N Alcalay, Leslie M Shaw, Peggy Taylor, Tao Xie, Paul Tuite, Claire Henchcliffe and 11 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Movement disorders : official journal of the Movement Disorder Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review.Journal of neural transmission (Vienna, Austria : 1996) · 2019
    Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Jennifer G GoldmanSection of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.ORCID 0000-0001-5014-7535
Howard AndrewsDivision of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA.
Amy AmaraDepartment of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Anna NaitoThe Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Roy N AlcalayDivision of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA.
Leslie M ShawDepartment of Pathology & Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Peggy TaylorBioLegend Inc, Dedham, USA.
Tao XieParkinson Disease and Movement Disorder Program, Department of Neurology, University of Chicago, Chicago, Illinois, USA.
Paul TuiteDepartment of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.
Claire HenchcliffeDepartment of Neurology, Weill Cornell Medical College, New York, New York, USA.
Penelope HogarthDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.
Samuel FrankDepartment of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA.
Marie-Helene Saint-HilaireDepartment of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA.
Mark FrasierThe Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Vanessa ArnedoThe Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Alyssa N ReimerThe Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Margaret SutherlandNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Christine Swanson-FischerNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Katrina GwinnNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Fox Investigation of New Biomarker Discovery
Un Jung KangDivision of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA.

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1M
NINDS Biomarker RepositoryU24NS095871 · NINDS · INDIANA UNIVERSITY INDIANAPOLIS · PI TATIANA M. FOROUD · 2015 to 2026
$18.3M
Neuroprotective mechanism of DJ-1 in Parkinson's diseaseR01NS053919 · NINDS · UNIVERSITY OF CHICAGO · PI KANG, UN JUNG · 2007 to 2011
$1.9M
NCATS NIH HHS UL1 TR002369NIA NIH HHS P30 AG010124NINDS NIH HHS R01 NS053919NINDS NIH HHS U24 NS095871
6 · The paper itself

Abstract

objectiveExamine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms.

backgroundCSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear.

methodsBioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined.

resultsCSF alpha-synuclein was lower in PD versus controls (P = .01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid

conclusionLower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid

Indexed as

Agedalpha-SynucleinAmyloid beta-PeptidesBiomarkersCohort StudiesCorrelation of DataCross-Sectional StudiesFemaleHumansMaleMiddle AgedParkinson DiseasePeptide FragmentsPostural BalanceSalivaSensation Disordersalpha-SynucleinAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersPeptide Fragmentstau Proteinsalpha-synucleinamyloidcerebrospinal fluidpostural instability gait difficultytau

Identifiers

PMID29205509
PMCPMC5836918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.